Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 11/20 | 0.48 |
| ▸ | ARNT | P27540 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MATK | P42679 | 1/20 | 0.42 |
| ▸ | FRK | P42685 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479505 | 0.94 | ARNT (0.44) | PRKCQARNTEPAS1GSK3AGSK3B | |
| SCHEMBL3812423 | 0.92 | PRKCQ (0.57) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3820581 | 0.91 | PRKCQ (0.58) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3819159 | 0.90 | PRKCQ (0.57) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3813870 | 0.88 | PRKCQ (0.46) | PRKCQARNTEPAS1GSK3AGSK3B | |
| SCHEMBL3815460 | 0.88 | PRKCQ (0.47) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3821517 | 0.88 | PRKCQ (0.49) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3813698 | 0.87 | PRKCQ (0.50) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3818753 | 0.87 | PRKCQ (0.48) | PRKCQGSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL3813090 | 0.86 | PRKCQ (0.46) | PRKCQARNTEPAS1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590334-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (US) | 2009-08-19 | — | — | EP | claimed |
| EP-1590334-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040242613-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004067516-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| EP-3046560-B1 | STEM CELL MODULATION II | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10124001-B2 | Stem cell modulation II | UNIVERSITY OF CANBERRA (AU) | 2018-11-13 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| EP-3185858-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | University of Canberra (AU) | 2017-07-05 | — | — | EP | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
| WO-2016029262-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2016-03-03 | — | — | WO | disclosed |
| EP-1590334-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (US) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885ARNT 4463/4885EPAS1 2962/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885ARNT 3041/4885EPAS1 1750/4885 |
| US-20040242613-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCD | PRKCQ 2/4885ARNT 4737/4885EPAS1 1425/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | PRKCQ 2/4885ARNT 2852/4885EPAS1 417/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885ARNT 3041/4885EPAS1 1750/4885 |
| US-10124001-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885ARNT 4463/4885EPAS1 2962/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885ARNT 4463/4885EPAS1 2962/4885 |
| US-20160354367-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885ARNT 4463/4885EPAS1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.